Novartis Q3 Performance
Novartis' Q3 performance was driven by fast growth in recently label-expanded drugs, despite facing generic competition. The company's net sales rose 7% in constant currencies to $13.9bn, in line with Wall Street forecasts.
Core operating income reached $5.46bn, slightly above consensus analyst predictions of $5.4bn. The oncology segment was a key driver of growth, with breast cancer treatment Kisqali (ribociclib) showing a 68% increase in Q3 2025 compared to Q3 2024.
- Net sales: $13.9bn (7% increase in constant currencies)
- Core operating income: $5.46bn
- Kisqali (ribociclib) growth: 68% in Q3 2025 compared to Q3 2024
The gold standard of business intelligence.
Author's summary: Novartis' Q3 performance driven by growth in new drugs.